Enliven Therapeutics, Inc (ELVN)
45.10
+0.24 (0.53%)
Upcoming Events
Latest Headlines
Form 4 Enliven Therapeutics, For: Jun 15 Filed by: OrbiMed Genesis GP LLC
June 17, 2026 7:45 PM - SEC Filing
Form SCHEDULE 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
June 17, 2026 7:42 PM - SEC Filing
Form 144 Enliven Therapeutics, Filed by: Hohl Benjamin
June 17, 2026 4:25 PM - SEC Filing
Form 144 Enliven Therapeutics, Filed by: ORBIMED CAPITAL LLC
June 15, 2026 9:24 PM - SEC Filing
Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
June 15, 2026 9:21 PM - SEC Filing
Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
June 15, 2026 9:19 PM - SEC Filing
ENLIVEN Therapeutics closes $460M public stock offering
June 15, 2026 4:40 PM - StreetInsider
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
June 15, 2026 4:40 PM - PR NewsWire
Form 8-K Enliven Therapeutics, For: Jun 11
June 12, 2026 4:56 PM - SEC Filing
Form 424B5 Enliven Therapeutics,
June 12, 2026 4:53 PM - SEC Filing
Enliven Therapeutics prices upsized public offering at $37.50 per share
June 11, 2026 10:40 PM - StreetInsider
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
June 11, 2026 10:40 PM - PR NewsWire
Form 424B5 Enliven Therapeutics,
June 11, 2026 5:28 PM - SEC Filing
Enliven Therapeutics launches $250 million public stock offering
June 11, 2026 4:05 PM - StreetInsider
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 11, 2026 4:05 PM - PR NewsWire
Form 8-K Enliven Therapeutics, For: Jun 11
June 11, 2026 8:09 AM - SEC Filing
Enliven Therapeutics reports phase 1 trial results for leukemia drug
June 11, 2026 8:01 AM - StreetInsider
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
June 11, 2026 8:00 AM - PR NewsWire
Form 8-K Enliven Therapeutics, For: Jun 09
June 10, 2026 6:02 AM - SEC Filing
Form 4 Enliven Therapeutics, For: Jun 05 Filed by: Kunkel Lori Anne
June 9, 2026 4:49 PM - SEC Filing
Stifel Starts Enliven Therapeutics (ELVN) at Buy
June 8, 2026 4:07 PM - StreetInsider
Form 144 Enliven Therapeutics, Filed by: Kunkel Lori Anne
June 5, 2026 4:30 PM - SEC Filing
Enliven Therapeutics schedules webcast for ELVN-001 clinical data
June 3, 2026 4:05 PM - StreetInsider
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
June 3, 2026 4:05 PM - PR NewsWire
Enliven Therapeutics (ELVN) PT Raised to $62 at Mizuho
June 2, 2026 6:41 AM - StreetInsider
Enliven Therapeutics to Present at Upcoming Investor Conferences
May 21, 2026 4:05 PM - PR NewsWire
Form 4 Enliven Therapeutics, For: May 18 Filed by: Collins Helen Louise
May 20, 2026 4:19 PM - SEC Filing
Form 144 Enliven Therapeutics, Filed by: Collins Helen Louise
May 18, 2026 4:29 PM - SEC Filing
Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc
May 15, 2026 5:30 PM - SEC Filing
Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Vestal Point Capital, LP
May 15, 2026 5:10 PM - SEC Filing
Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
May 15, 2026 4:42 PM - SEC Filing
Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Fairmount Funds Management LLC
May 15, 2026 4:39 PM - SEC Filing
Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Commodore Capital LP
May 15, 2026 4:39 PM - SEC Filing
Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc
May 15, 2026 9:12 AM - SEC Filing
Enliven Therapeutics to present ELVN-001 trial data at EHA congress
May 12, 2026 9:54 AM - StreetInsider
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
May 12, 2026 9:53 AM - PR NewsWire
Guggenheim Starts Enliven Therapeutics (ELVN) at Buy
May 12, 2026 3:03 AM - StreetInsider
Enliven Therapeutics (ELVN) PT Raised to $59 at Goldman Sachs
May 8, 2026 6:43 AM - StreetInsider
Form 10-Q Enliven Therapeutics, For: Mar 31
May 7, 2026 4:20 PM - SEC Filing
Form 8-K Enliven Therapeutics, For: May 07
May 7, 2026 4:14 PM - SEC Filing
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
May 7, 2026 4:05 PM - PR NewsWire
Form 144 Enliven Therapeutics, Filed by: Lyssikatos Joseph P
April 30, 2026 4:22 PM - SEC Filing
Form ARS Enliven Therapeutics, For: Dec 31
April 27, 2026 4:11 PM - SEC Filing
Form DEFA14A Enliven Therapeutics,
April 27, 2026 4:09 PM - SEC Filing
Form DEF 14A Enliven Therapeutics, For: Jun 09
April 27, 2026 4:07 PM - SEC Filing
Enliven Therapeutics (ELVN) PT Raised to $55 at Clear Street
April 27, 2026 5:15 AM - StreetInsider
Form 4 Enliven Therapeutics, For: Apr 17 Filed by: Collins Helen Louise
April 21, 2026 8:40 PM - SEC Filing
Form PRE 14A Enliven Therapeutics, For: Jun 09
April 15, 2026 4:07 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Enliven Therapeutics (ELVN)
April 8, 2026 7:12 AM - StreetInsider
Jones Trading Assumes Enliven Therapeutics (ELVN) at Buy
April 6, 2026 4:16 PM - StreetInsider
Form 144 Enliven Therapeutics, Filed by: Lyssikatos Joseph P
March 31, 2026 4:30 PM - SEC Filing
Form 144 Enliven Therapeutics, Filed by: Phillips Andrew John
March 31, 2026 4:27 PM - SEC Filing
Form 4 Enliven Therapeutics, For: Mar 25 Filed by: Collins Helen Louise
March 27, 2026 4:57 PM - SEC Filing
Enliven Therapeutics (ELVN) PT Raised to $56 at H.C. Wainwright
March 26, 2026 6:42 AM - StreetInsider
Form 144 Enliven Therapeutics, Filed by: Collins Helen Louise
March 25, 2026 4:29 PM - SEC Filing
Clear Street on Enliven Therapeutics (ELVN): MRK's TERN acquisition 'sharpens investment case for ELVN-001'
March 25, 2026 10:04 AM - StreetInsider
Enliven Therapeutics (ELVN) PT Raised to $45 at Jones Trading
March 25, 2026 7:59 AM - StreetInsider
Enliven Therapeutics stock surges 28% on Merck-Terns deal
March 25, 2026 7:39 AM - StreetInsider
Form 144 Enliven Therapeutics, Filed by: Patel Anish
March 24, 2026 4:26 PM - SEC Filing
Enliven Therapeutics (ELVN) PT Raised to $45 at Mizuho, 'Still an under-rated asset in the CML space'
March 24, 2026 3:04 PM - StreetInsider
Full Article List
